Introduction

Liquid biopsy is rapidly transforming cancer detection and diagnosis thanks to its non-invasive nature and ability to provide real-time insights into a patient's health. This innovative approach allows for the analysis of biomarkers in biofluid samples—such as various circulating DNA fragments termed cell-free DNA (cfDNA)—marking a significant leap forward in precision medicine.

Challenges in Sequencing cfDNA

Despite its promise, sequencing cfDNA presents hurdles: its inherent fragility and often low concentrations in samples can lead to low library yields and insufficient mean target coverage. This complicates the identification of rare biomarkers and variants essential for effective treatment strategies.

Twist Bioscience's Solution

Recognizing these challenges, biotechnology leader Twist Bioscience has launched the Twist cfDNA Library Preparation Kit, a revolutionary solution designed to enhance high-yield cfDNA libraries for next-generation sequencing (NGS).

Dr. Emily M. Leproust, CEO and co-founder of Twist Bioscience, explains, "Our new cfDNA Library Preparation Kit addresses the pressing challenges in liquid biopsy applications and cancer research. With our advanced technology, clinicians can now achieve high performance even when sample quantities are low."

Performance Improvements

What's even more impressive? Twist Bioscience’s analysis indicates a two-fold improvement in conversion rates compared to existing cfDNA library preparation kits. This translates to significantly enhanced yield, superior mean target coverage, and improved detection sensitivity for rare variants—crucial for diagnosing and monitoring complex cancers. The kit works effectively with cfDNA concentrations as low as 1 to 20 ng/ml, setting a new benchmark in the field.

"By developing a novel ligase and optimizing various protocols, we've successfully increased conversion efficiency and reduced reaction times regardless of sample size," added Dr. Leproust, emphasizing the kit’s robust capability.

Detecting Circulating Tumor DNA (ctDNA)

One of the primary metrics of success in using this kit is its contribution to detecting circulating tumor DNA (ctDNA)—molecular signatures gleaned from cancer cells that can indicate prognosis and guide treatment plans. The robust performance of the Twist cfDNA Library Preparation Kit promises to refine ctDNA assays, allowing for more accurate cancer diagnostics.

Global Impact and Efficiency

Since its February 2024 release, the Twist kit has generated excitement among oncology laboratories worldwide. In one notable instance, a lab in the Asia-Pacific region reported a remarkable 30% increase in coverage for low-frequency somatic mutations, achieved with a reduction in PCR cycles. This improvement not only shortens turnaround time but also enhances reliability by minimizing biases.

Designed for efficiency, the Twist cfDNA Library Preparation Kit produces sequence-ready libraries within just two hours while maintaining low error rates. It comes in two variations: one tailored for whole genome sequencing and another optimized for target enrichment.

Complementary Products

To complement the kit, Twist Bioscience also offers the Twist cfDNA Pan-Cancer Reference Standard v2, providing high-quality control samples for establishing analytical limits and monitoring assay quality. With over 400 variant sites across 84 genes, this reference standard is seamlessly integrated into Twist’s target enrichment solutions, facilitating more precise cancer research.

The Future of Liquid Biopsy

Twist Bioscience is poised to advance the applications of liquid biopsy in diverse areas—ranging from early cancer detection to tumor profiling and monitoring molecular transformations in patients. Their commitment to enhancing their NGS portfolio firmly positions them as leaders in the vital field of precision oncology and personalized medicine.

"The incorporation of cfDNA into NGS workflows represents a pivotal advance in both research and clinical practices. At Twist Bioscience, we're dedicated to pushing the frontiers of NGS technology to enrich cancer research," concluded Dr. Leproust.

Conclusion